Clinical Trial Update: 25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing 25-G vitrectomy with ranibizumab or with triamcinolone acetonide for proliferative diabetic retinopathy in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Diabetic Retinopathy

Drugs mentioned

• Ranibizumab (ranibizumab)
• TRIAMCINOLONE ACETONIDE (TRIAMCINOLONE ACETONIDE)

Snippet

Sponsor: JUNYAN ZHANG | Conditions: Proliferative Diabetic Retinopathy | Phase 3 | Status: UNKNOWN